Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Merck turns to Prometheus to bolster its post-Keytruda strategy
For $10.8bn the pharma giant gains a promising new mechanism, and adds immunology as a future investment area.
If at first... pharma’s most drawn-out development timelines revealed
Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.
Prometheus takes on Pfizer in inflammatory bowel diseases
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
